Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 MRNA Vaccine Booster Shot: A Case Report

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2021 Dec 13

PMID 34901098

Citations 29

Authors

Serge Goldman

Dominique Bron

Thomas Tousseyn

Irina Vierasu

Laurent Dewispelaere

Pierre Heimann

Elie Cogan

Michel Goldman

Affiliations

Soon will be listed here.

Abstract

Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.

Citing Articles

The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement.

Bellavite P, Donzelli A, Isidoro C J Clin Med. 2024; 13(23).

PMID: 39685749 PMC: 11642405. DOI: 10.3390/jcm13237291.

Nodal T-Follicular Helper Cell Lymphoma, Angioimmunoblastic-Type, Diagnosed in a Patient with Psoriasis Following COVID-19 Vaccination under Adalimumab Treatment: A Causal Association?.

Hsieh C, Yu S, Lee J, Tsai T Indian J Dermatol. 2024; 69(3):264-267.

PMID: 39119326 PMC: 11305510. DOI: 10.4103/ijd.ijd_93_23.

Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report.

Khatri J, Tahboub I, Anwar K, Masoudi M, Graffeo V, Jamil M J Investig Med High Impact Case Rep. 2024; 12:23247096241231645.

PMID: 38761096 PMC: 11102676. DOI: 10.1177/23247096241231645.

Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan.

Gibo M, Kojima S, Fujisawa A, Kikuchi T, Fukushima M Cureus. 2024; 16(4):e57860.

PMID: 38721172 PMC: 11077472. DOI: 10.7759/cureus.57860.

Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review.

Olszewska B, Zaryczanska A, Nowicki R, Sokolowska-Wojdylo M Front Med (Lausanne). 2024; 11:1325478.

PMID: 38660418 PMC: 11041019. DOI: 10.3389/fmed.2024.1325478.

References

Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H . Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma. Cancer Med. 2020; 9(15):5509-5518. PMC: 7402824. DOI: 10.1002/cam4.3226. View

Loetsch C, Warren J, Laskowski A, Vazquez-Lombardi R, Jandl C, Langley D . Cytosolic Recognition of RNA Drives the Immune Response to Heterologous Erythrocytes. Cell Rep. 2017; 21(6):1624-1638. DOI: 10.1016/j.celrep.2017.10.044. View

Turner J, OHalloran J, Kalaidina E, Kim W, Schmitz A, Zhou J . SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021; 596(7870):109-113. PMC: 8935394. DOI: 10.1038/s41586-021-03738-2. View

Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M . Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Acad Radiol. 2021; 28(8):1058-1071. PMC: 8088218. DOI: 10.1016/j.acra.2021.04.007. View

Horwitz S, OConnor O, Pro B, Illidge T, Fanale M, Advani R . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2018; 393(10168):229-240. PMC: 6436818. DOI: 10.1016/S0140-6736(18)32984-2. View

Treglia G, Cuzzocrea M, Muoio B, Elzi L . PET findings after COVID-19 vaccination: "Keep Calm and Carry On". Clin Transl Imaging. 2021; 9(3):209-214. PMC: 8117802. DOI: 10.1007/s40336-021-00430-3. View

Nawwar A, Searle J, Lyburn I . Features of Systemic Immune Response From COVID-19 Vaccination on 18F-FDG PET/CT. Clin Nucl Med. 2021; 47(1):e89-e90. DOI: 10.1097/RLU.0000000000003859. View

Shin M, Hyun C, Choi Y, Choi J, Lee K, Cho Y . COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine. Clin Nucl Med. 2021; 46(10):814-819. PMC: 8411598. DOI: 10.1097/RLU.0000000000003800. View

Cohen D, Hazut Krauthammer S, Wolf I, Even-Sapir E . Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021; 48(6):1854-1863. PMC: 8003894. DOI: 10.1007/s00259-021-05314-2. View

10.

Cohen M, Nirula A, Mulligan M, Novak R, Marovich M, Yen C . Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA. 2021; 326(1):46-55. PMC: 8176388. DOI: 10.1001/jama.2021.8828. View

11.

Cortes J, Ambesi-Impiombato A, Couronne L, Quinn S, Kim C, da Silva Almeida A . RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell. 2018; 33(2):259-273.e7. PMC: 5811310. DOI: 10.1016/j.ccell.2018.01.001. View

12.

Xu G, Lu Y . COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT. Clin Nucl Med. 2021; 46(4):353-354. DOI: 10.1097/RLU.0000000000003597. View

13.

Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y . Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014; 46(2):171-5. DOI: 10.1038/ng.2872. View

14.

Goldman S, Bron D, Tousseyn T, Vierasu I, Dewispelaere L, Heimann P . Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report. Front Med (Lausanne). 2021; 8:798095. PMC: 8656165. DOI: 10.3389/fmed.2021.798095. View

15.

Pardi N, Hogan M, Naradikian M, Parkhouse K, Cain D, Jones L . Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018; 215(6):1571-1588. PMC: 5987916. DOI: 10.1084/jem.20171450. View

16.

Weeks J, OBrien S, Rosenspire K, Dubroff J, Pantel A . Evolving Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT Following 2-Dose COVID-19 Vaccination. Clin Nucl Med. 2021; 46(12):1011-1012. PMC: 8575109. DOI: 10.1097/RLU.0000000000003711. View

17.

Treglia G, Cuzzocrea M, Giovanella L, Elzi L, Muoio B . Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis. Pharmaceuticals (Basel). 2021; 14(8). PMC: 8401863. DOI: 10.3390/ph14080762. View

18.

Ozutemiz C, Krystosek L, Church A, Chauhan A, Ellermann J, Domingo-Musibay E . Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients. Radiology. 2021; 300(1):E296-E300. PMC: 7909072. DOI: 10.1148/radiol.2021210275. View